 |
BioWorld-International-2003-05-28
Medivir, GSK Agree To EUR86M Deal For Phase I HIV Candidate
Medivir, GSK Agree To EUR86M Deal For Phase I HIV Candidate
Medivir AB entered its largest drug development deal to date, a pact worth up to €86 million with GlaxoSmithKline plc to develop its HIV drug MIV-210. The news sent the Huddinge, Sweden-based company's share price soaring by almost 50 percent during trading on the Stockholm Stock Exchange last week, to close at SEK61 Friday. (BioWorld International)